Table 4.
Clinical and functional status at one-year follow-up by APR levels among biologic-naïve patients
| |
Neither APR elevated |
APR levels discordant |
Both APR elevated |
P
value |
|---|---|---|---|---|
| n = 1,012 | n = 487 | n = 324 | ||
| mHAQ |
0.28 ± 0.40 |
0.32 ± 0.43 |
0.34 ± 0.46 |
0.0623 |
| CDAI |
9.65 ± 10.11 |
9.75 ± 9.81 |
10.85 ± 11.17 |
0.2243 |
| Tender joints |
2.64 ± 4.93 |
2.41 ± 4.33 |
2.83 ± 5.17 |
0.4378* |
| Swollen joints |
2.90 ± 4.66 |
2.91 ± 4.54 |
3.52 ± 5.04 |
0.1299* |
| Patient global assessment |
26.23 ± 24.77 |
28.36 ± 25.62 |
28.68 ± 26.53 |
0.1149 |
| MD global assessment |
14.52 ± 14.82 |
15.61 ± 15.38 |
16.43 ± 15.85 |
<0.0001 |
| Biologic use | 150 (14.84%) | 83 (17.08%) | 67 (20.68%) | 0.0437 |
*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.